Fig. 6From: Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapyAssessment of immunogenicity of selected candidate peptides. The immunogenicity of 12 peptides from 5 candidate genes was assessed by CD8+ T cell priming and tetramer staining assays (Table 2). Left column: tetramer staining of CD8+ T cells primed with the indicated ccRCC-specific peptide. Middle column (negative control): ccRCC-specific peptide tetramer staining of CD8+ T cells primed with an unrelated, HLA-matched peptide. Right column (UV peptide): tetramer staining of positively primed CD8+ T cells with the respective UV-sensitive peptide tetramerBack to article page